Navigation Links
Abeome Forms First Class Scientific Advisory Board
Date:9/10/2008

ATHENS, Ga., Sept. 10 /PRNewswire/ -- Abeome Corporation, a Georgia-based biotech company, today announced the formation of its Scientific Advisory Board (SAB) to collaborate on the development of Abeome's ovarian cancer project and to select and guide future therapeutic and diagnostic projects for the company.

The SAB will be led by scientific founder Richard Meagher, PhD, Chief Scientific Officer for Abeome, Distinguished Research Professor at the University of Georgia, and inventor of Abeome's patented monoclonal antibody technology. The SAB will consist of:

Christine Debouck, PhD, President of Ardennes Biosciences LLC and formerly Senior VP in R&D at GlaxoSmithKline, is renowned for her expertise in target validation, disease knowledge and compound characterizations as well as for her broad scientific applications of biotechnology, genomics and biomarker discovery in pre-clinical and clinical development, and biomarker evaluation with an emphasis in oncology and infectious diseases. Dr. Debouck brings 24 years of experience in directing creative science in diverse areas of research.

Jeff Boyd, PhD, Chief Scientific Officer and Sr. VP at Fox Chase Cancer Center in Philadelphia, has an international reputation as one of the leading scientists in the study of molecular genetics of women's cancers. Dr. Boyd was named Distinguished Cancer Scholar by the Georgia Cancer Coalition. His long-term research focus has studied molecular genetics of ovarian cancer with emphasis on hereditary predisposition.

Linda Matsuuchi, PhD, Associate Director of the Life Sciences Institute at the University of British Columbia, has a distinguished research career focused on intracellular trafficking and cell signaling of specific membrane receptors on the cell surface of B lymphocytes, the source of antibody production.

"We are pleased to assemble such an incredibly talented team of scientists to serve on our SAB and to participate in target validation on our ovarian cancer therapeutic project. Their active participation provides Abeome with valuable expertise in pre-clinical and clinical trials, unparalleled knowledge of ovarian cancer pathology, and years of immunology experience specific to monoclonal antibody development," states Abeome CEO, Mike Wanner.

"The company will deploy its monoclonal antibody technology to rapidly develop a pipeline of therapeutic candidates in a number of cancer areas and will benefit by these individual's commitment to our mission. They join an already outstanding group of Abeome scientists, biotech-oriented Board of Directors, and scientific founder, Dr. Richard Meagher to form a team of world-class scientists to insure Abeome's future success."

About Abeome

Abeome Corporation is a biotechnology company dedicated to leveraging its proprietary hybridoma technology to accelerate and improve the development of monoclonal antibodies for life sciences. Abeome owns an exclusive license for the technology from the University of Georgia Research Foundation and has garnered significant support from the Georgia Research Alliance. Its current focus is on developing a cancer therapeutic and diagnostic for ovarian cancer.

For more information on Abeome, visit http://www.abeomecorp.com.


'/>"/>
SOURCE Abeome Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Satyam Forms Partnership with Sciformix to Provide Comprehensive Drug Safety Management
2. Neogen Forms Mexican Subsidiary
3. BioStorage Technologies Forms Scientific Advisory Board with Leading Life Science Experts
4. American Oriental Bioengineering Forms Science and Technology Advisory Committee
5. IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance
6. Agrenco Informs Sale of Biodiesel at ANP Auction
7. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
8. International Federation of Clinical Chemistry Forms Partnership With the Labs Are Vital(TM) Initiative
9. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
10. febit Forms Scientific Advisory Board
11. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... ... Nipro Corporation (Osaka, Japan) and Transonic Systems Inc. (New York, USA) announced ... and sales rights for all non-OEM Transonic products in Japan. As partners for more ... Nipro - Transonic JV is a natural next step to advance best practices and ...
(Date:1/21/2017)... Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)("Interpace" ... useful molecular diagnostic tests and pathology services, today ... purchase agreement with three  institutional investors to purchase ... in a registered direct offering.  In a concurrent ... to the same investors warrants to purchase 855,000 ...
(Date:1/21/2017)... Aratana Therapeutics, Inc. (NASDAQ: PETX ... development and commercialization of innovative biopharmaceutical products for companion ... North America 2016. ... on the FDA approval of three innovative therapeutics in ... (capromorelin oral solution) and NOCITA ® (bupivacaine liposome ...
(Date:1/20/2017)... ... January 20, 2017 , ... The two newest companies to join the ... Vironika, a spin out from The Wistar Institute, and Sanguis, launched by a trio ... Market Street. , Vironika is developing a treatment for a chronic viral infection ...
Breaking Biology Technology:
(Date:1/12/2017)... PORTLAND, Oregon and PUNE, India , January 12, 2017 ... Technology Market: Opportunities and Forecasts, 2015 - 2022," projects that the global biometric technology ... CAGR of 19.4% from 2016 to 2022. Continue Reading ... ... ...
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CES® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
(Date:12/22/2016)... 22, 2016 SuperCom (NASDAQ:   ... for the e-Government, Public Safety, HealthCare, and Finance sectors announced today ... been selected to implement and deploy a community-based supportive services program ... California , further expanding its presence in the state. ... This new program, which ...
Breaking Biology News(10 mins):